Answers are grounded in this paper and cite their sources.
Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) treat overweight or obesity with or without diabetes. This review aims to evaluate the effects of GLP-1 RAs on weight and cardiometabolic measures. This systematic review and meta-analysis of randomized trials from PubMed, Scopus, Web of Science, and Embase followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Two reviewers extracted the data and assessed the quality with the Cochrane Risk of Bias 2 (RoB 2) tool. Thirteen randomized controlled trials were included. We concluded that GLP-1 RAs reduced mean percentage body weight by -12.79% (95% CI: -15.12 to -10.46), BMI by -4.80 kg/m² (95% CI: -6.24 to -3.36), waist circumference by -9.78 cm (95% CI: -11.47 to -8.09), systolic blood pressure (BP) by -6.32 mmHg (95% CI: -7.92 to -4.72), and diastolic BP by -1.95 mmHg (95% CI: -3.21 to -0.69). Risk ratios for ≥5%, ≥10%, ≥15%, and ≥20% weight loss were 2.98, 5.56, 9.50, and 15.00, respectively. Tirzepatide showed greater reductions than semaglutide. GLP-1 RAs, particularly tirzepatide, achieve substantial weight loss and improve cardiometabolic risk factors.
No takes yet. Share an insight, caveat, or question.
Elbashir et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: